Literature DB >> 26601065

Modified porous tantalum rod technique for the treatment of femoral head osteonecrosis.

Emilios E Pakos1, Panayiotis Megas1, Nikolaos K Paschos1, Spyridon A Syggelos1, Antonios Kouzelis1, Georgios Georgiadis1, Theodoros A Xenakis1.   

Abstract

AIM: To study a modified porous tantalum technique for the treatment of osteonecrosis of the femoral head.
METHODS: The porous tantalum rod was combined with endoscopy, curettage, autologous bone grafting and use of bone marrow aspirates from iliac crest aspiration in 49 patients (58 hips) with a mean age of 38 years. The majority of the patients had idiopathic osteonecrosis, followed by corticosteroid-induced osteonecrosis. Thirty-eight hips were of Steinberg stage II disease and 20 hips were of stage III disease. Patients were followed for 5 years and were evaluated clinically with the Merle D'Aubigne and Postel score and radiologically. The primary outcome of the study was survival based on the conversion to total hip arthroplasty (THA). Secondary outcomes included deterioration of the osteonecrosis to a higher disease stage at 5 years compared to the preoperative period and identification of factors that were associated with survival. The Kaplan-Meier survival analysis was performed to evaluate the survivorship of the prosthesis, and the Fisher exact test was performed to test associations between various parameters with survival.
RESULTS: No patient developed any serious intraoperative or postoperative complication including implant loosening or migration and donor site morbidity. During the 5-year follow up, 1 patient died, 7 patients had disease progression and 4 hips were converted to THA. The 5-year survival based on conversion to THA was 93.1% and the respective rate based on disease progression was 87.9%. Stage II disease was associated with statistically significant better survival rates compared to stage III disease (P = 0.04). The comparison between idiopathic and non-idiopathic osteonecrosis and between steroid-induced and non-steroid-induced osteonecrosis did not showed any statistically significant difference in survival rates. The clinical evaluation revealed statistically significantly improved Merle d'Aubigne scores at 12 mo postoperatively compared to the preoperative period (P < 0.001). The mean preoperative Merle d'Aubigne score was 13.0 (SD: 1.8). The respective score at 12 mo improved to 17.0 (SD: 2.0). The 12-mo mean score was retained at 5 years.
CONCLUSION: The modified porous tantalum rod technique presented here showed encouraging outcomes. The survival rates based on conversion to THA are the lowest reported in the published literature.

Entities:  

Keywords:  Avascular necrosis; Bone grafting; Femoral head; Survival; Tantalum rod

Year:  2015        PMID: 26601065      PMCID: PMC4644871          DOI: 10.5312/wjo.v6.i10.829

Source DB:  PubMed          Journal:  World J Orthop        ISSN: 2218-5836


  37 in total

1.  Clinical and radiological outcome of the treatment of osteonecrosis of the femoral head using the osteonecrosis intervention implant.

Authors:  Thilo Floerkemeier; Fritz Thorey; Dorothea Daentzer; Matthias Lerch; Phillip Klages; Henning Windhagen; Gabriela von Lewinski
Journal:  Int Orthop       Date:  2010-01-30       Impact factor: 3.075

2.  Combination treatment of biomechanical support and targeted intra-arterial infusion of peripheral blood stem cells mobilized by granulocyte-colony stimulating factor for the osteonecrosis of the femoral head: a randomized controlled clinical trial.

Authors:  Qiang Mao; Weidong Wang; Taotao Xu; Shanxing Zhang; Luwei Xiao; Di Chen; Hongting Jin; Peijian Tong
Journal:  J Bone Miner Res       Date:  2015-04       Impact factor: 6.741

3.  Porous tantalum implant in early osteonecrosis of the hip: preliminary report on operative, survival, and outcomes results.

Authors:  Michael S Shuler; Michael D Rooks; James R Roberson
Journal:  J Arthroplasty       Date:  2007-01       Impact factor: 4.757

4.  Tantalum rod implantation and vascularized iliac grafting for osteonecrosis of the femoral head.

Authors:  Dewei Zhao; Yao Zhang; Weiming Wang; Yupeng Liu; Zhigang Li; Benjie Wang; Xiaobing Yu
Journal:  Orthopedics       Date:  2013-06       Impact factor: 1.390

5.  Free vascularized fibular grafting for the treatment of postcollapse osteonecrosis of the femoral head. Surgical technique.

Authors:  J Mack Aldridge; Keith R Berend; Eunice E Gunneson; James R Urbaniak
Journal:  J Bone Joint Surg Am       Date:  2004-03       Impact factor: 5.284

Review 6.  Core decompression versus nonoperative management for osteonecrosis of the hip.

Authors:  M A Mont; J J Carbone; A C Fairbank
Journal:  Clin Orthop Relat Res       Date:  1996-03       Impact factor: 4.176

Review 7.  Intraoperative fat embolism during core decompression and bone grafting for osteonecrosis of the hip: report of 3 cases and literature review.

Authors:  Joseph Christopher Schaffer; Farshad Adib; Quanjun Cui
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2014-06

8.  Osteonecrosis of the femoral head. Hip salvaging with implantation of a vascularized fibular graft.

Authors:  K N Malizos; P N Soucacos; A E Beris
Journal:  Clin Orthop Relat Res       Date:  1995-05       Impact factor: 4.176

9.  Treatment of osteonecrosis of the femoral head with free vascularized fibular grafting. A long-term follow-up study of one hundred and three hips.

Authors:  J R Urbaniak; P G Coogan; E B Gunneson; J A Nunley
Journal:  J Bone Joint Surg Am       Date:  1995-05       Impact factor: 5.284

10.  Biocompatibility and osteogenic properties of porous tantalum.

Authors:  Qian Wang; Hui Zhang; Qijia Li; Lei Ye; Hongquan Gan; Yingjie Liu; Hui Wang; Zhiqiang Wang
Journal:  Exp Ther Med       Date:  2015-01-23       Impact factor: 2.447

View more
  8 in total

1.  Enhanced repair of segmental bone defects in rabbit radius by porous tantalum scaffolds modified with the RGD peptide.

Authors:  Hui Wang; Qijia Li; Qian Wang; Hui Zhang; Wei Shi; Hongquan Gan; Huiping Song; Zhiqiang Wang
Journal:  J Mater Sci Mater Med       Date:  2017-02-14       Impact factor: 3.896

2.  Repair of non-traumatic femoral head necrosis by marrow core decompression with bone grafting and porous tantalum rod implantation.

Authors:  Keyun Peng; Yu Wang; Jifeng Zhu; Chengling Li; Ziming Wang
Journal:  Pak J Med Sci       Date:  2020 Sep-Oct       Impact factor: 1.088

3.  Outcome after a new porous tantalum rod implantation for treatment of early-stage femoral head osteonecrosis.

Authors:  Wei Huang; Xuan Gong; Steve Sandiford; Xiaoqiang He; Feilong Li; Yuwan Li; Ziming Liu; Leilei Qin; Jianye Yang; Sizheng Zhu; Jiawei Wang; Xiaolin Tu; Lei Ye; Ning Hu
Journal:  Ann Transl Med       Date:  2019-09

Review 4.  Corticosteroid-induced Osteonecrosis of the Femoral Head: Detection, Diagnosis, and Treatment in Earlier Stages.

Authors:  Li-Hua Liu; Qing-Yu Zhang; Wei Sun; Zi-Rong Li; Fu-Qiang Gao
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

5.  AAV-Anti-miR-214 Prevents Collapse of the Femoral Head in Osteonecrosis by Regulating Osteoblast and Osteoclast Activities.

Authors:  Cheng Wang; Weijia Sun; Shukuan Ling; Yu Wang; Xin Wang; Haoye Meng; Yuheng Li; Xueling Yuan; Jianwei Li; Ruoxi Liu; Dingsheng Zhao; Qiang Lu; Aiyuan Wang; Quanyi Guo; Shibi Lu; Hua Tian; Yingxian Li; Jiang Peng
Journal:  Mol Ther Nucleic Acids       Date:  2019-10-18       Impact factor: 8.886

Review 6.  Treatment of non-traumatic avascular necrosis of the femoral head (Review).

Authors:  Ning Liu; Changming Zheng; Qinglong Wang; Zhipeng Huang
Journal:  Exp Ther Med       Date:  2022-03-10       Impact factor: 2.447

Review 7.  The Clinical Application of Porous Tantalum and Its New Development for Bone Tissue Engineering.

Authors:  Gan Huang; Shu-Ting Pan; Jia-Xuan Qiu
Journal:  Materials (Basel)       Date:  2021-05-18       Impact factor: 3.623

Review 8.  Tissue Engineering Strategies for Treating Avascular Necrosis of the Femoral Head.

Authors:  Sumit Murab; Teresa Hawk; Alexander Snyder; Sydney Herold; Meghana Totapally; Patrick W Whitlock
Journal:  Bioengineering (Basel)       Date:  2021-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.